SINT (SINTX Technologies) ROCE % : -231.84% (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is SINTX Technologies ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. SINTX Technologies's annualized ROCE % for the quarter that ended in Sep. 2024 was -231.84%.

SINTX Technologies ROCE % Historical Data

The historical data trend for SINTX Technologies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SINTX Technologies ROCE % Chart

SINTX Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-59.11

-40.56

-39.79

-89.76

-81.94

SINTX Technologies Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-94.85	-76.75	-27.27	-68.35	-231.84

SINTX Technologies ROCE % Calculation

SINTX Technologies's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-8.257	/	( ( (15.773 - 8.078)	+	(15.365 - 2.906) )	/ 2 )
	=	-8.257	/	( (7.695	+	12.459)	/ 2 )
	=	-8.257	/	10.077
	=	-81.94 %

SINTX Technologies's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-24.92	/	( ( (15.296 - 3.021)	+	(11.303 - 2.08) )	/ 2 )
	=	-24.92	/	( ( 12.275	+	9.223 )	/ 2 )
	=	-24.92	/	10.749
	=	-231.84 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

SINTX Technologies (NAS:SINT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

SINTX Technologies ROCE % Related Terms

Thank you for viewing the detailed overview of SINTX Technologies's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

SINTX Technologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SINTX Technologies Inc (NAS:SINT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0A8S:UK

Address

1885 West 2100 South, Salt Lake City, UT, USA, 84119

Website

https://www.sintx.com

SINTX Technologies Inc is an advanced ceramics company, focused on providing solutions in a variety of biomedical, technical, and antipathogenic applications. It has grown from focusing primarily on the research, development, and commercialization of medical devices manufactured with silicon nitride to becoming an advanced ceramics company engaged in diverse fields, including biomedical, technical, and antipathogenic applications. Its biomedical products are biocompatible, bioactive, antipathogenic, and to have superb bone affinity. Spinal implants made from SINTX silicon nitride have been successfully implanted in humans in the US, Europe, Brazil, and Taiwan.

Executives

David W. Truetzel	director	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET, SALT LAKE CITY UT 84119
David Francis O'brien	officer: Chief Operating Officer	1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Ty Lombardi	officer: VP Finance	C/O AMEDICA CORPORATION, 1885 W 2100 SOUTH, SALT LAKE CITY UT 84119
Eric A Stookey	director	5677 AIRLINE ROAD, ARLINGTON TN 38002
Gordon Esplin	officer: Vice President, Finance	C/O AMEDICA CORPORATION, 1885 WEST 2100 SOUTH, SALT LAKE CITY UT 84119
Kevin Ontiveros	officer: See Remarks	C/O IMARX THERAPEUTICS INC, 1635 EAST 18TH STREET, TUCSON AZ 85719
Arthur Karl Kipke	10 percent owner	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
Jay M Moyes	director, officer: Chief Fnancial Officer
Vytas Rupinskas	officer: SVP, Marketing	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Eric K. Olson	director, officer: President and CEO	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119
James P. Abraham	officer: SVP, Global Sales	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Christopher Whitfield	officer: Chief Commercial Officer	C/O AMEDICA CORPORATION, 1885 WEST 1200 STREET, SALT LAKE CITY UT 84119
Max Link	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Kevin L Davis	officer: Chief Operating Officer	9149 SOUTH MONROE PLAZA WAY, SUITE B, SANDY UT 84070
Jeffrey S. White	director	C/O AMEDICA CORPORATION, 1885 WEST 2100 STREET SOUTH, SALT LAKE CITY UT 84119